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Abstract
To survive and metastasize, tumors interact with surrounding tissues by secreting growth factors and cytokines. In re-
turn, surrounding host tissues respond by changing their secretome. Numerous factors theoretically function as
therapeutic targets or biomarkers of cancer growth and metastatic risk. However, it is unclear if these factors are
tumor-derived or actually represent the host defense. To analyze the concentrations of tumor- and microenvironment-
derived factors associated with neoplastic growth, we used ELISA-based arrays specific for murine or human proteins
to establish a profile of tumor- or host-derived factors circulating in the plasma or within the platelets upon human tumor
implantation into mice. Many factors characterized as tumor-derived were actually secreted by host tissues. This study
uncovered the origin of various cytokines and revealed their circulation methods. We found that tumor-produced cyto-
kines are predominantly sequestered in platelets. Sequestered proteins are protected from degradation and, thus, may
be functional at metastatic sites. These findings identify tumor-specific targets for the detection and prevention of tumor
growth and metastasis. As predicted by our model, monocyte chemotactic protein 1 and tumor necrosis factor αmay
be biomarkers for human cancers. Thus, our study identified several potential biomarkers that might be predictive of
prostate cancer.
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Introduction
The mechanisms of tumor growth and metastasis have been studied
for decades, and yet, in 2008, more people died of cancer than from
cardiovascular diseases, thus making cancer the number one cause of
death in the United States. Many aspects of tumor development remain
enigmatic, precluding development of efficient diagnostic tests and
treatments. The intricate interactions of a growing tumor with its micro-
environment and macroenvironment make cancerous tissue the most
elusive part of an organism. It seems that tumor functions as an ultimate
parasite and uses an organism’s resources to promote its own growth and
to invade into distant locations. The growing tumor secretes a number
of growth factors, cytokines, and proteases, which are transported by the
host vascular system, reachingmultiple organs and tissues. Many factors
seem to be secreted by the tumor secretomes of various cancers, such as
vascular endothelial growth factors (VEGFs) to promote tumor vascu-
larization [1,2], matrix metalloproteinases (MMPs) to modify the extra-
cellular matrix [1,3], cytokines to attract hematopoietic cells from bone
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marrow [4,5], and growth factors involved in bone turnover to prepare
future metastatic sites. Tumor activity triggers diverse reactions in host
tissues, including angiogenic processes, recruitment of inflammatory
cells, and changes in hemostasis. As a result, the host organism changes
its own secretome, possibly as a defensive measure. Yet, many factors
produced by surrounding tissues might promote tumor growth and
its invasion rather than inhibit it. Although many factors circulating
in the blood of a tumor-bearing organism have been identified and even
proposed as diagnostic markers [1–3,6,7], it is unclear whether they are
part of the tumor or host secretome.
In many instances, the tumor secretome is aimed at communica-
tion with distant organs, and therefore, many components should be
“hidden” and protected while being transported to their target. Indeed,
it was recently shown that whereas some factors circulate freely within
the plasma, others are sequestered within platelets and might be selec-
tively released on platelet activation [8]. Depleting platelets in tumor-
bearing mice triggers intratumor hemorrhaging and stimulates tumor
cell apoptosis within the hemorrhagic area [9]. In addition to the effects
on tumor stability, thrombocytopenia diminished tumor cell prolifera-
tion. Thus, platelets seem to be required for continued tumor growth.
In addition, platelets can directly bind to cells within the tumor, which,
in turn, may permit the loading of platelets with tumor-derived factors
[10] and promote tumor cell migration and invasiveness. Platelets also
bind tumor cells in the circulation, which may assist tumor cells in
evading the immune system [11]. Thus, it is not surprising that inhi-
bition of platelet–tumor cell interactions diminishes the formation of
metastases [10,11].
In this study, we compared the tumor secretome with the host re-
sponse to cancer growth by measuring not only freely circulating
growth factors but also the ones stored and released by platelets. Fur-
ther, on the basis of our animal model data, we predicted that mono-
cyte chemotactic protein-1/CCL2 (MCP-1) and tumor necrosis factor
α (TNFα) might serve as markers of tumor presence. Indeed, this was
confirmed in patients with prostate cancer.
Materials and Methods
Mouse Injection
Eight-week-old male NOD.CB17-Prkdcscid/J (Jackson Laboratory,
BarHarbor,ME)mice were injected subcutaneously with PBS (control;
n = 5) or 4 × 105 LNCaP-C4-2 human prostate cancer cells in PBS per
side (n = 5). LNCaP-C4-2 cells were provided by Dr Lloyd A. Culp
(Case Western Reserve University, Cleveland, OH). Tumors were per-
mitted to grow for 28 days before mice were euthanized.
Platelet Isolation and Activation
While mice were anesthetized, the vena cava of age- and sex-matched
mice was exposed, and blood was collected from the vein into acid-
citrate-dextrose buffer containing 1 μg/ml prostaglandin E1 (Sigma, St
Louis, MO). Platelets and plasma were separated from the platelet-
rich plasma of blood pooled from four to five mice by gel filtration,
as previously described [12]. The activated supernatant was collected
by centrifugation after platelets were treated with 100 nM phorbol
12-myristate 13-acetate (PMA; Sigma), 1 mM protease inhibitors (com-
plete Mini; Roche, Indianapolis, IN), and 500 μMmouse PAR-4-amide
(Bachem, Torrance, CA) at 37°C for 45 minutes to stimulate release of
granular contents.
Protein Arrays
The plasma and activated platelet supernatants were assayed with
custom-designedQuantibody protein arrays fromRayBiotech (Norcross,
GA). A human-specific array was used to detect circulating proteins de-
rived from the tumor. A mouse-specific array was used to detect circulat-
ing proteins derived from the host. Arrays were assayed according to the
manufacturer’s protocol. Fluorescently labeled arrays (green fluorescence,
Cy3 channel; 555 nm excitation and 565 nm emission) were analyzed
using an Axon 4000B (Molecular Devices, Sunnyvale, CA) scanner in
the LRI Genomics Core. Values of four replicates for each protein were
extracted using the Axon Gene Pix Pro 4.1 software and analyzed using
the RayBiotech Custom Raybio Q-Analyzer software, which uses stan-
dardized dilutions of each protein to create standard curves used in de-
termining the concentration (pg/ml) of each protein in the samples.
Clinical Samples
An approval from the Cleveland Clinic Institutional Review Board
was obtained before the initiation of blood sample collection from
patients undergoing radical prostatectomy at the Cleveland Clinic
Glickman Urological and Kidney Institute. A patient consent form
was specifically created for the study with clearly stated goals and
for describing the purpose of our research. Whole blood (3-4 ml)
was collected by venipuncture in Na2EDTA tubes (BD Biosciences,
San Jose, CA) from patients before surgery and 3 months postopera-
tively. Plasma and platelets were isolated from whole blood by centri-
fugation and gel filtration, as previously described [12]. Platelets were
activated with 50 μM human TRAP-6-amide (Bachem), 1 mM pro-
tease inhibitors, and 100 nM PMA to stimulate granule release.
ELISAs
Isolated plasma and platelet releasates from six patients were
assayed using the RayBiotech Human MCP-1 ELISA or Human
TNFα ELISA according to the manufacturer’s instructions. Two
separate samples from each patient at each time point were analyzed
and compared with a standard curve to obtain the concentration
(pg/ml) of each protein in the samples.
Statistical Analysis
Student’s t test analysis or one-way ANOVA with Newman-Keuls
posttest was used to determine statistical significance using GraphPad
Prism 4.03 software (La Jolla, CA). *P < .05, **P < .01, and ***P < .005.
Results
To compare the tumor secretome to the host tissue defense, we injected
human prostate cancer cells into immunocompromised mice (mice
without tumors served as controls) and performed a protein array analy-
sis of human or murine proteins in two compartments: plasma and
platelet releasates. Candidate proteins were chosen on the basis of their
potential roles in cancer progression, invasion, and bone metastasis.
Our species-specific system allowed for the detection and quantitative
analysis of tumor and host secretomes separately. On the basis of anti-
body specificity, we measured 15 and 22 proteins of host and tumor
origin, respectively. No cross-reaction of antibodies was observed be-
cause control samples from mice without tumors were negative for
human proteins. A complete list of assayed growth factors and cytokines
secreted by host or tumor and their respective values in plasma and
platelets is presented in Table 1.
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Tumor-Derived Proteins Enter the Circulation
Concentrations of proteins secreted by tumor are presented in
Table 1 (right column). Owing to the specificity of the arrays for
human proteins, the cytokines studied were not detected in control
samples, which were without human tumors (Figure 1). To further
determine the impact of each tumor-derived cytokine, we calculated the
percent contributions of tumor and host to the total concentrations
of circulating cytokines and growth factors (Figure 2). Several impor-
tant factors, such as thrombopoietin (TPO), TNFα, granulocyte–
macrophage colony-stimulating factor (GM-CSF), and stromal-derived
factor-1α (SDF-1α), were secreted primarily by the tumor with a neg-
ligible amount produced by host. In plasma, TPO, TNFα, and GM-
CSF were solely of tumor origin (Figure 2,A and B). The tumor-derived
proteins present at the highest levels in plasmawere transforming growth
factor (TGF)-β1, TPO, soluble urokinase-type plasminogen activator
receptor (uPAR), hepatocyte growth factor (HGF), interleukin (IL)-6,
and SDF-1α, with concentrations ranging from approximately 9000 to
430,000 pg/ml (Figure 1A; Table 1). TheMMPs-1, -3, -9, and -13 were
secreted at high concentrations (350-12,750 pg/ml) into the plasma
of mice bearing tumors (Figure 1, A and B; Table 1). Further, TNFα,
VEGF, granulocyte colony-stimulating factor (G-CSF), tissue inhib-
itor of metalloproteinase (TIMP)-2, GM-CSF, IL-1β, and macro-
phage colony-stimulating factor (M-CSF) circulated at lower levels
(80-3300 pg/ml) in the plasma (Figure 1B; Table 1). Interestingly,
MMP-13 was 1.79-fold higher in the plasma compared with the plate-
lets. Tumor-derived G-CSF, MMP-9, and IL-1β were present at concen-
trations more than 50-fold lower than their host-derived counterparts
in the plasma and the platelets (Table 1). Thus, tumor-derived cytokines
can enter the host circulation.
Tumor-Derived Proteins Are Sequestered within Platelets
In platelet releasates, 100% of the GM-CSF, 97% of the TPO, and
60% of the TNFα were tumor-derived (Figure 2, A and B). GM-CSF
was exclusively tumor-produced and was present at equal concentra-
tions in the plasma and platelets (Table 1). Tumor-derived TNFα
and TPO were preferentially stored in platelets where their levels were
2.57- and 1.58-fold higher, respectively, than in plasma (Table 2). In-
terestingly, MCP-1 was completely tumor-derived and localized exclu-
sively to platelets (Figure 2B), with no tumor-derived MCP-1 found
in plasma and no host-derived MCP-1 present in platelets or plasma
(Table 1). Thus, platelet-stored MCP-1 might serve as a promising
marker of tumor presence. Likewise, tumor-derived soluble receptor
activator of NF-κB (RANK), RANK ligand (RANKL), MMP-2,
and TIMP-1 were present entirely in the platelet compartment and
not in the plasma (Table 1). Therefore, they were present at a con-
centration 1000- to 5800-fold higher in the platelets compared with
the plasma (Table 2). In platelets, tumor-derived TPO, uPAR, IL-6,
SDF-1α, and MMP-1 concentrations ranged from approximately
13,750 to 73,750 pg/ml (Figure 1C ; Table 1), whereas the amount
Table 1. Growth Factor and Cytokine Concentration Values in Plasma and Platelet Releasates.
Cytokine Host-Derived Tumor-Derived
Control Plasma
(pg/ml)
Control Releasate
(pg/ml)
Tumor Plasma
(pg/ml)
Tumor Releasate
(pg/ml)
Control Plasma
(pg/ml)
Control Releasate
(pg/ml)
Tumor Plasma
(pg/ml)
Tumor Releasate
(pg/ml)
G-CSF 33,687.5 ± 2321.4* 9842.4 ± 1452.2 57,659.1 ± 9312.4* 9076.3 ± 2028.7 0 ± 0 0 ± 0 1004.3 ± 72.5† 59.9 ± 40.6†
GM-CSF 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 269.4 ± 8.2‡ 282.5 ± 55.4‡
HGF 5965.6 ± 1268.4§ 12,119.0 ± 594.1 27,017.2 ± 4024.8§ 5519.9 ± 1472.5 0 ± 0 0 ± 0 7292.9 ± 2161.0† 4235.5 ± 673.9†
IL-1β 5275.7 ± 665.7§ 3422.1 ± 842.5* 20,152.1 ± 5530.1§ 5622.0 ± 1918.3* 0 ± 0 0 ± 0 78.5 ± 25.4¶ 88.1 ± 6.8¶
IL-6 0 ± 0# 19,622.4 ± 2220.8 9506.7 ± 3220.1# 23,512.8 ± 2197.8 0 ± 0 0 ± 0 5739.5 ± 1998.4** 18,078.0 ± 745.4**
MCP-1 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0‡,†† 7100.5 ± 777.0‡,††
M-CSF 0 ± 0# 449.8 ± 57.3* 1337.4 ± 320.8# 1315.5 ± 171.6* 0 ± 0 0 ± 0 81.8 ± 5.5** 1332.3 ± 74.8**
MMP-1 —‡‡ —‡‡ —‡‡ —‡‡ 0 ± 0 0 ± 0 12,763.8 ± 1309.5¶ 13,742.7 ± 1341.5¶
MMP-2 —‡‡ —‡‡ —‡‡ —‡‡ 0 ± 0 0 ± 0 0 ± 0†† 2100.4 ± 256.5††
MMP-3 —‡‡ —‡‡ —‡‡ —‡‡ 0 ± 0 0 ± 0 5410.1 ± 1753.6¶ 4603.3 ± 284.1¶
MMP-9 33,502.1 ± 3601.8* 18,717.9 ± 2046.6 48,258.0 ± 9952.3* 18,911.5 ± 3208.0 0 ± 0 0 ± 0 350.1 ± 165.0¶ 267.6 ± 135.6¶
MMP-13 —‡‡ —‡‡ —‡‡ —‡‡ 0 ± 0 0 ± 0 1027.6 ± 278.2† 573.7 ± 81.3†
OPG 40,446.4 ± 4821.8* 5139.4 ± 360.5 50,616.8 ± 2534.0* 3764.5 ± 263.0 —‡‡ —‡‡ —‡‡ —‡‡
OPN 260,695.0 ± 6186.7* 1182.9 ± 77.1 385,459.5 ± 5903.4* 985.5 ± 92.3 —‡‡ —‡‡ —‡‡ —‡‡
RANK —‡‡ —‡‡ —‡‡ —‡‡ 0 ± 0 0 ± 0 0 ± 0†† 5957.0 ± 1714.9††
RANKL 95,875.4 ± 9753.8 37,442.4 ± 6209.7 148,956.2 ± 19,582.6 43,341.1 ± 4373.9 0 ± 0 0 ± 0 0 ± 0†† 5890.6 ± 607.3††
SDF-1α 0 ± 0# 2568.3 ± 1013.9 2209.0 ± 1010.2# 2621.8 ± 825.0 0 ± 0 0 ± 0 4437.3 ± 1480.6** 17,563.6 ± 1039.0**
TGF-β1 —
‡‡ —‡‡ —‡‡ —‡‡ 0 ± 0 0 ± 0 428,248.4 ± 83,344.0** 839,997.0 ± 54,189.0**
TIMP-1 —‡‡ —‡‡ —‡‡ —‡‡ 0 ± 0 0 ± 0 0 ± 0†† 1540.2 ± 275.9††
TIMP-2 —‡‡ —‡‡ —‡‡ —‡‡ 0 ± 0 0 ± 0 606.9 ± 126.9¶ 552.1 ± 59.0¶
TNFα 0 ± 0 14,503.4 ± 2195.0§§ 0 ± 0 5773.9 ± 840.0§§ 0 ± 0 0 ± 0 3299.1 ± 294.2** 8489.0 ± 534.6**
TPO 0 ± 0 4901.5 ± 808.7 0 ± 0 3446.3 ± 278.7 0 ± 0 0 ± 0 46,585.5 ± 29,310.7** 73,686.7 ± 2940.7**
uPAR —‡‡ —‡‡ —‡‡ —‡‡ 0 ± 0 0 ± 0 17,876.1 ± 6969.3¶ 17,665.3 ± 2108.6¶
VEGF 2697.2 ± 227.2* 769.3 ± 61.4 3802.3 ± 145.7* 668.5 ± 145.7 0 ± 0 0 ± 0 1821.7 ± 488.0† 939.3 ± 180.1†
Plasma and platelet releasates were isolated from mice bearing LNCaP-C4-2 tumors (Tumor) and without tumors (Control) as described in Materials and Methods. Species-specific microarrays for
murine (Host-derived) and human (Tumor-derived) proteins were used to determine cytokine and growth factor concentrations, represented as mean ± SEM.
*For host derived proteins: 1.1- to 3-fold increase by tumor (VEGF, OPN, OPG, MMP-9, IL-1β, G-CSF, and RANKL).
†For tumor-derived proteins: proteins present in plasma at the higher levels than in platelets (G-CSF, HGF, MMP-13, and VEGF).
‡For tumor-derived proteins: factors produced by tumor but not by the host (GM-CSF and MCP-1).
§For host-derived proteins: four- to six-fold increase by tumor (HGF and IL-1β).
¶For tumor-derived proteins: proteins at equal levels in plasma and platelets.
#For host derived proteins: secreted by host only in response to tumor (M-CSF, IL-6, and SDF-1α) with negligible amounts present in control mice.
**For tumor-derived proteins: proteins present in platelets at the higher levels compared with plasma (IL-6, M-CSF, SDF-1α, TGF-β1, TNFα, and TPO).
††For tumor-derived proteins: tumor-derived factors accumulated in platelets but absent in plasma.
‡‡Not determined due to appropriate antibodies being unavailable.
§§For host-derived proteins: total amount of protein was decreased in the presence of tumor (TNFα).
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of TNFα, MCP-1, soluble RANK, RANKL, MMP-3, and HGF in
platelet releasate from mice bearing tumors ranged from 4000 to 8500
pg/ml (Figure 1, C and D; Table 1). MMP-2, TIMP-1, M-CSF, and
VEGF were present at concentrations between approximately 950 and
2100 pg/ml (Figure 1D; Table 1). At the lowest concentration in plate-
lets were tumor-derived MMP-13, TIMP-2, GM-CSF, and IL-1β,
with concentrations from approximately 85 to 575 pg/ml (Figure 1D;
Table 1). Tumor-derived VEGF is 1.4-fold higher in platelets com-
pared with host, demonstrating that tumor-derived proteins can be
preferentially stored in platelets. In addition, tumor-derived M-CSF
and IL-6 were 12.21- and 4.35-fold higher, respectively, in platelets
compared with plasma (Table 2). These observations indicate that
the uptake of certain growth factors by platelets is not driven by their
concentration gradient but that it seems to be selective.
Figure 1. Concentrations of prostate tumor-derived cytokines circulating in plasma and platelets. Plasma (A, B) and releasates from
platelets (C, D) activated with 500 μM PAR-4 and 100 nM PMA were isolated from mice injected subcutaneously with LNCaP-C4-2
(C42, black columns) or PBS (Control, white columns). A species-specific array for human proteins was used to determine the concen-
trations of tumor-derived cytokines; represented as mean values ± SEM. No tumor-derived proteins were found in the plasma or plate-
lets of control mice, demonstrating the specificity of the array. *P < .05, **P < .01, and ***P < .005 versus control by one-way ANOVA.
Figure 2. Predominantly tumor contributions to cytokine concentrations in plasma and platelet releasate. (A and B) Plasma and releasates
from platelets activated with 500 μM PAR-4 and 100 nM PMA (Platelets) were isolated from mice injected subcutaneously with human
LNCaP-C4-2 cells. Species-specific protein arrays were used to determine the concentrations of murine (Host Derived, white columns)
and human (Tumor Derived, black columns) cytokines and growth factors. Concentrations are represented asmean values± SEM. Percent-
ages represent the tumor contribution to the total concentration of each protein in plasma or platelets.
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Remarkably, TGF-β1 was present at the highest concentration in the
platelet compartment (Figure 1C). TGF-β1 promotes tumor progression
and skeletal metastasis of several cancers [6,7]. Most studies describe
increased TGF-β1 within the plasma of cancer patients; however, the
origin of TGF-β1 in patient plasma has remained an open question.
Our analysis showed that TGF-β1 was produced by the tumor reaching
concentrations of 428,248 and 839,997 pg/ml in plasma and platelets,
respectively, of tumor-bearing mice (Figure 1, A and C ; Table 1). Inter-
estingly, tumor-derived TGF-β1 was 1.96-fold higher in the platelets
compared with the plasma (Table 2). Thus, TGF-β1 was found at the
highest concentration of all the proteins tested in both the plasma and
platelets. In agreement with previous studies, it seems that platelets serve
as a key reservoir of TGF-β1 in the circulation [4,13].
Previous studies have postulated that SDF-1α is produced by the
stromal cells surrounding the tumor [14]. In our study, SDF-1α circu-
lated in the plasma and platelets and was predominantly produced by
the tumor (87% and 81%, respectively; Figure 2A). The tumor-derived
SDF-1α concentration was 3.96-fold higher in the platelets of mice
compared with plasma (Table 2). Platelet-derived SDF-1α has been
shown to stimulate the adhesion and recruitment of bone marrow–
derived endothelial progenitors to arterial thrombi [15]. This mecha-
nism may also be used by tumors to promote vascularization and sup-
port tumor growth, thus accounting for the high levels of SDF-1α
produced by the tumor.
Host-Derived Proteins Are Concentrated in Plasma
As shown in Table 1, host tissues responded to the presence of tumor
and contributed significantly to the pool of factors in plasma as well as
in platelets (left column). Many of these factors were increased in re-
sponse to tumor growth in the plasma of mice (Figure 3, A and B).
Previous studies have shown that both the tumor and the microenvi-
ronment were able to secrete several cytokines, including HGF, IL-6,
SDF-1α, M-CSF, and VEGF [14,16–18]. Remarkably, we found that
HGF, M-CSF, IL-6, and even VEGF were largely host-derived in the
plasma: 79%, 71%, 62%, and 68%, respectively (Figure 4, A and B).
At lower concentrations, ranging from 2000 to 27,000 pg/ml, host-
derived HGF, IL-6, VEGF, and M-CSF were increased in the plasma
of mice bearing tumors (Figure 3B; Table 1). Host-derived HGF levels
were 4.53-fold higher in the plasma of mice with tumors compared
with control (Table 3). Host-derived SDF-1α levels in plasma were in-
creased from 0 to 2209 pg/ml in response to tumor presence, whereas
the platelet concentrations did not change (Table 1). In addition, host-
derived M-CSF and IL-6 were present only in the plasma of animals
with tumor (Table 1). Thus, some proteins in the plasma of mice with
tumors are produced by both the host and the tumor.
In response to the presence of a tumor, host tissues upregulated
secretion of other factors, including RANKL, G-CSF, MMP-9, and
IL-1β. These proteins can interact with the immune system and may
Figure 3. Concentrations of host tissue–derived cytokines circulating
in plasma and platelets in the presence or absence of tumor. Plasma
(A, B) and releasates from platelets (C) activated with 500 μM PAR-4
and 100 nM PMA were isolated from mice injected subcutaneously
with LNCaP-C4-2 tumor cells (C42, black columns) or PBS (Control,
white columns). A species-specific array for murine proteins was
used to determine the concentrations of microenvironment-derived
cytokines represented as mean values ± SEM. *P < .05, **P < .01,
and ***P < .005 versus control by one-way ANOVA.
Table 2. Fold Change of Tumor-Derived Proteins in Activated Platelets over Plasma in Tumor
Bearing Mice.
Cytokine Fold Change Activated Releasate: Plasma
IL-6 4.35
MCP-1 7100.49
M-CSF 12.21
MMP-2 1050.19
RANK 4467.74
RANKL 5890.61
SDF-1α 3.96
TGF-β1 1.96
TIMP-1 1155.15
TNFα 2.57
TPO 1.58
Plasma and releasates from platelets activated with 500 μM PAR-4 and 100 nM PMAwere isolated
from mice bearing subcutaneous LNCaP-C4-2 tumors. A human-specific microarray was used to
analyze the protein concentrations that are represented as fold change of mean activated platelet
releasate concentrations over mean plasma.
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control the host tissue’s defense against invading cancer cells. Host-
derived RANKL, G-CSF, MMP-9, and IL-1β represented 100%, 98%,
99%, and 99.6%, respectively, of the total amount of protein secreted
into plasma (Figure 4,C andD). In the plasma, host-derived osteopontin
(OPN), RANKL, and G-CSF circulated at high concentrations in re-
sponse tumor; ranging from approximately 57,500 to 385,500 pg/ml
(Figure 3A; Table 1). Osteoprotegrin (OPG) and MMP-9 circulated at
concentrations around 50,000 pg/ml in the plasma of mice with tumors
(Table 1). Host-derived G-CSF and MMP-9 were 1.71 and 1.44 higher,
respectively, in the plasma of mice with tumors compared with con-
trols but were unchanged in the platelets (Table 3). In addition, host-
derived IL-1β and RANKLwere 3.82- and 1.55-fold higher, respectively,
in the plasma of mice with tumors compared with controls (Table 3).
Another two factors involved in tumor metastasis were upregulated
in the presence of tumor: host-derived OPG and OPN by 1.25- and
1.47-fold, respectively (Table 3). Thus, several factors are upregulated
by the host tissue in response to the tumor, although some may exacer-
bate tumor growth.
VEGF is the most studied tumor-secreted proangiogenic factor, and
it was shown to be present at high levels in plasma and in platelets of
cancer patients [1,2,8,19]. These studies, however, do not differentiate
between tumor- and host-derived VEGF. Surprisingly, more than a half
of VEGF in plasma was secreted by the host tissues (Figure 4B). In
response to tumor, host tissues upregulated their VEGF secretion into
the plasma from 2697 to 3802 pg/ml (Figure 3B), whereas no changes
occurred in platelet VEGF concentrations (Table 1). Both host- and
tumor-derivedVEGFswere at higher concentrations (5.69- and 1.94-fold,
respectively) in the plasma compared with platelets of mice bearing
tumors (Table 1). Thus, our data demonstrate that the changes seen
Figure 4. Predominantly host contributions to cytokine concentrations in plasma and platelet releasate. (A–D) Plasma and releasates from
platelets activatedwith 500 μMPAR-4 and 100 nMPMA (Platelets) were isolated frommice injected subcutaneously with human LNCaP-C4-2
cells. Species-specific protein arrays were used to determine the concentrations of murine (Host Derived, white columns) and human (Tumor
Derived, black columns) cytokines and growth factors. Concentrations are represented as mean values ± SEM. Percentages represent the
contribution of host (in black) or tumor (in white) to the total protein in plasma or platelets.
Table 3. Fold Change of Host-Derived Proteins in Mice Bearing Tumors over Control Mice.
Cytokine Plasma Activated Platelets
G-CSF 1.71 0.94
HGF 4.53 0.46
IL-1β 3.82 1.67
IL-6 9406.73 1.21
M-CSF 1337.45 2.97
MMP-9 1.44 1.02
OPG 1.25 0.74
OPN 1.47 0.84
RANKL 1.55 1.17
SDF-1α 2208.98 1.03
TNFα —* 0.40
TPO —* 0.70
VEGF 1.41 0.88
Plasma and releasates from platelets activated with 500 μM PAR-4 and 100 nM PMAwere isolated
from mice injected with subcutaneous LNCaP-C4-2 tumors or PBS (control). A murine-specific
microarray was used to analyze the protein concentrations that are represented as fold change of
mean tumor concentrations over mean control.
*None detected.
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in the plasma VEGF levels of patients may represent the combined ef-
fect of tumor- and host-produced VEGF.
Host-Derived Proteins Do Not Accumulate in Platelets
Interestingly, only the concentrations of TNFα, HGF, OPG, and
M-CSF were altered significantly in the platelet releasate of mice bear-
ing tumors compared with control (Figure 3C ; Table 1). Of these
factors, only host-derived M-CSF increased 2.97-fold (Table 3) in re-
sponse to tumor in the platelet compartment from 450 to 1315 pg/ml
(Table 1), whereas OPG, HGF, and TNFα were reduced (Figure 3C).
Host-derived G-CSF, MMP-9, IL-1β, and RANKL were 99%, 99%,
98%, and 88%, respectively, of the total platelet compartment contents
(Figure 4, C and D); however, their concentrations were largely un-
affected by the tumor presence. Host-derived IL-1β, IL-6, and RANKL
were 1.67-, 1.21-, and 1.17-fold higher, respectively, in the platelets of
mice with tumors compared with controls (Table 3), although the
change was not significant. The platelet levels of HGF, M-CSF, IL-6,
and VEGF were approximately 50% tumor-derived and 50% host-
derived (Figure 4, A and B). Overall, the amount of total host-derived
HGF was increased by 1.80-fold in the presence of tumor. Host-
derived TNFα and TPO were absent in the plasma, and their levels in
platelets were reduced in the presence of tumors by 2.5- and 1.40-fold,
respectively (Table 3). Thus, our data indicate that host-derived proteins
circulate at greater concentrations in the plasma in response to tumor
growth and are not preferentially sequestered in platelets. Some cytokines
and growth factors were produced by host tissues as a defense mecha-
nism against further tumor growth and invasion.However,many of these
factors can also promote tumor growth and invasiveness, rendering the
host defense futile.
On the basis of our results, it seems that tumor-derived proteins were
more likely to be selectively accumulated in platelets comparedwith host-
derived proteins. In general, 11 (50%) of 22 tested tumor-derived pro-
teins were enriched in the platelet compartment over plasma compared
with 3 (20%) of 15 tested host-derived proteins. Several tumor-derived
factors, such as MMP-1, MMP-3, MMP-13, uPAR, and TIMP-2, were
of approximately equal concentrations in plasma and platelets.
MCP-1 and TNFα as Biomarkers for Tumor Presence in
Prostate Cancer Patients
Our studies demonstrated that MCP-1 was secreted solely by the
tumor andwas present exclusively in the platelets of tumor-bearingmice
(Figure 2B). TNFα was also completely tumor-derived within the
plasma, and tumor-secreted TNFα comprised 60% of the platelet com-
partment (Figure 2A). To assess the validity of our findings in cancer
patients, we determined the levels of MCP-1 and TNFα in prostate
cancer patients before surgery and 3 months after radical prostatectomy.
Owing to the timing of blood collection from patients, platelets were
partially activated (28%) before processing and, at least in part, had
released their α-granular contents into plasma (data not shown). In-
deed, we were able to detect MCP-1 not only in the platelet com-
partment (2.38 ± 0.07 pg/108 platelets) but also in the plasma (26.40 ±
4.83 pg/ml) of patients with prostate cancer before surgery. Never-
theless, as predicted on the basis of our animal model, total MCP-1
was present at a 1.44-fold higher concentration in patients before sur-
gery (84.09 ± 14.86 pg/ml) than 3 months after surgery (58.47 ±
2.77 pg/ml; Figure 5A). Thus, MCP-1 in the blood was largely pro-
duced by the tumor, comparable to our mouse model.
TNFα was also present in both the plasma and the platelets of pa-
tients with prostate cancer before surgery. In our mouse model, tumor
implantation resulted in decreased host-derived TNFα in platelets
compared with control animals (Figure 3C ). Conversely, tumor-derived
TNFα compensated for the decrease in host production, comprising
100% of plasma TNFα and 60% of platelet TNFα (Figure 2A). Thus,
in our mouse model, total platelet TNFα concentrations remained con-
stant (Table 1). Conversely, TNFα in the plasma of tumor-bearing
animals was solely tumor-derived (Figure 1C), and TNFα was absent
in the plasma of control animals. Correspondingly, in patients, the TNFα
concentrationwas equal in platelets before (76.16 ± 0.85 pg/108 platelets)
and after surgery (78.17 ± 0.99 pg/108 platelets), suggesting that the
host tissue may upregulate production to maintain a homeostasis of
TNFα in the platelets after tumor removal. Interestingly, similar to our
model, the plasma TNFα concentration was 1.72-fold higher in patients
before surgery (146.08 ± 10.05 pg/ml) compared with 3 months post-
operatively (85.05 ± 3.19 pg/ml; Figure 5B). These data support the
Figure 5. MCP-1 and TNFα concentrations decrease after tumor
removal in prostate cancer patients. Plasma and releasate from
platelets activated with 50 μM TRAP-6 and 100 nM PMA were
isolated from whole blood collected from patients undergoing radi-
cal prostatectomy (Preoperative) and 3 months after tumor removal
(3 month post-op) and analyzed by ELISA (n= 12). (A) Mean concen-
trations ± SEM of combined plasma and releasate concentrations
are shown. (B) Mean concentrations ± SEM of plasma concentra-
tions are shown. *P< .05 and **P< .01 versus Preoperative by Stu-
dent’s t test.
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notion that the tumor substantially contributes to the levels of MCP-1
and TNFα in blood. Thus, MCP-1 and TNFα might serve as indica-
tors of the tumor presence and/or progression. To improve detection
methods, not only plasma but also activated platelet contents should be
used for diagnostic tests.
Discussion
In this study, we reveal the origin of various cancer-related cytokines
and growth factors and establish their methods of circulation during
tumor growth. Using species-specific protein arrays, we quantified
the concentrations of tumor- and host-derived factors in the plasma
and in the platelet compartment. Our main conclusions are the fol-
lowing: 1) Tumors secrete a number of factors that circulate in the
plasma and/or that are sequestered by platelets and can be released on
platelet activation. Among these many factors, tumor-derived TGF-
β1 is present at the highest concentration in platelet releasate. 2) Sev-
eral tumor-derived factors are present exclusively in platelets: MCP-1,
MMP-2, RANK, RANKL, and TIMP-1. 3) Host tissues respond to
the tumor presence by upregulating their secretion of a number of
factors. The most dramatic increases stimulated by tumor were ob-
served for HGF and IL-1β. Several factors, namely, IL-6, M-CSF,
and SDF-1α, are present in the plasma of tumor-bearing animals
but not control animals. These factors, however, can be found in
the platelet compartment of both control and tumor-bearing mice.
4) Tumor-derived factors are more likely to be accumulated in plate-
lets compared with host-derived factors. For example, during tumor
growth, M-CSF of host origin is equally distributed between the plasma
and platelets; however, tumor-derived M-CSF is 12-fold higher in plate-
lets than in plasma (Table 2). Conversely, host-derived proteins remain
mainly in the plasma. 5) It seems that accumulation of tumor-derived
factors in platelets is not driven by the gradient of their concentration
in plasma because there are factors absent in the plasma but present
in platelets (tumor-derived MCP-1, MMP-2, RANK, RANKL, and
TIMP-1; and host-derived TNFα and TPO), and there are factors
abundant in the plasma but not in platelets (host-derived G-CSF, HGF,
IL-1β, MMP-9, and OPG).
Our results demonstrate that the tumor produces high levels of
cytokines and growth factors known to promote tumor growth and
metastasis and that these factors can be sequestered in and released by
platelets. Many of these factors secreted by tumors or their micro-
environment might serve as new biomarkers of cancer progression or
as targets for cancer treatment and, therefore, warrant further study.
The correlations between the plasma concentrations of certain cyto-
kines with cancer severity in patients have been documented, as sum-
marized in Table W1. For example, plasma IL-6 was increased in
patients with a high-stage cancer and correlated with the metastatic
potential of the tumor (Table W1) [20,21]. Our study shows that
the presence of tumor increases both tumor- and host-derived IL-6 in
plasma. In addition, significant amounts of IL-6 are stored in platelets.
Another study demonstrated that MCP-1 levels in plasma are higher
in cancer patients compared with healthy individuals (Table W1)
[22]. We show that MCP-1 is entirely produced by tumor and is stored
in platelets, which makes this chemokine a very attractive biomarker
of and therapeutic target for cancer. In addition, there were multiple re-
ports implicating MMPs in cancer progression. For example, MMP-2
was shown to serve as a marker of prostate and thyroid cancers [23].
Our study shows that a majority of tumor-secreted MMP-2 is stored
in platelets; therefore, measurements should be performed using the
platelet releasate not plasma as a source of MMP-2. Of interest are fac-
tors involved in bone metabolism and, potentially, in tumor metastasis
to the bone, such as soluble RANK and RANKL [24–26]. Indeed, a
previous study reported that, in neuroblastoma patients, RANKL is
increased with stage, metastasis, and unfavorable tissue pathohistology
[24]. We show that in plasma, the presence of tumor results in up-
regulation of RANKL, which is exclusively produced by host tissues
and not by tumor. Conversely, tumor-derived RANKL is stored in plate-
lets. Along with RANKL, platelet-stored soluble RANK seems to serve
as a promising biomarker. RANKL and soluble RANK are believed to
target bone tissues and control tumor metastasis [27,28]; thus, it seems
that communication between tumor and bone may be mediated by
platelets as carriers of factors stored in their granules. Thus, we demon-
strate for the first time that many factors believed to be produced by
tumor are, in fact, secreted by the host tissues in response to the tumor
presence. For example, less than half of total VEGF is tumor-derived;
thus, host tissues serve as a main source of this growth factor in tumor-
bearing animals.
In many cases, the concentrations we report here are several fold
higher than those reported for humans (Table W1), which is due to
the overall ratio of tumor to body volume in our animal model and,
possibly, to the sensitivity of our method. The concentration of
TNFα measured in our clinical samples was higher than the previ-
ously reported value of 3.95 pg/ml in the serum of prostate cancer
patients [21]. Conversely, MCP-1 measured in our study was slightly
lower than the reported 365.26 pg/ml in the serum of patients with
acute myeloid leukemia [22]. These discrepancies may be due to dif-
ferences in antibodies, collection methods, the blood component
studied, patient demographics, or type of cancer studied. However,
overall, the values are comparable. For example, MMP-1 concentra-
tion in plasma is 15,000 and 13,000 pg/ml on the basis of literature
and our xenograft measurements, respectively. For many other fac-
tors, such as M-CSF, MMP-9, TNFα, and SDF-1α, host- and tumor-
derived proteins combine to produce similar concentrations to those
seen in humans. Thus, our system seems to be equally or more sensitive
for a number of potential biomarkers. Most importantly, we show that
platelet releasate represents a better source for many of these proteins.
Our study identifies several tumor-derived factors that are dra-
matically enriched in platelets compared with plasma. Platelet seques-
tered proteins likely play a role in the interactions between the tumor
and distant organs, including future metastatic sites, because seques-
tered proteins can be released at higher concentrations at specific lo-
cations, whereas proteins in the plasma could be degraded, used, or
neutralized anywhere in the body. Intriguingly, we found that tumor-
derived proteins were preferentially sequestered within platelets and
released on platelet activation. Thus, platelets, as specific carriers of
the tumor secretome, seem to be crucial mediators of interactions be-
tween the tumor and host tissues. In summary, our study identified
several potential biomarkers of cancer progression and therapeutic tar-
gets for cancer treatments. Many of these proteins are not present in
plasma and must be measured in the platelet compartment or in platelet-
rich plasma.
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Table W1. Reported Cytokine Plasma Levels in Patients with Cancer.
Cytokine Reported Plasma Concentration, mean (pg/ml) Cancer Tested References Notes on Correlation
GM-CSF 0.32 Prostate Adler et al. [1] No correlation with stage
HGF 499.00 (PT) Prostate Gupta et al. [2] Predictor of metastasis
1,062.00 (Met)
IL-6 0.36 (RL) Colorectal Kim et al. [3] Increased risk when over RL
1.94 (PT) Prostate Adler et al. [1] Increased with stage and metastasis
93.15 (Met)
MCP-1 365.26 AML Mazur et al. [4] Increased over control
M-CSF —* Breast Lawicki et al. [5] Correlated with stage
9700.00 (Met) Scholl et al. [6] Increased with metastasis and stage
4200.00 (PT)
867.00 (Met) McDermott et al. [7] Increased with metastasis
—* Prostate Ide et al. [8] Increased with bone metastasis
627.00 (Met) McDermott et al. [7] Increased with bone metastasis
604.00 Head and neck McDermott et al. [7] Increased over control
MMP-1 700.00 Thyroid Komorowski et al. [9] No difference compared with control
MMP-13 15,200.00 (PT) Prostate Morgia et al. [10] Increased with metastasis, decreased with treatment
28,600.00 (Met)
MMP-2 —* Ovarian Manenti et al. [11] No difference compared with control
839,000.00 (PT) Prostate Morgia et al. [10] Increased with metastasis, decreased with treatment
1,230,00.00 (Met)
568,900.00 Colorectal Tutton et al. [12] Decreased with treatment
605,950.00 Thyroid Komorowski et al. [9] Increased over control
MMP-9 51,400.00 (RL) NSCLC Tamura et al. [13] Increased with stage. Levels above RL correlate with LN metastasis
—* Ovarian Manenti et al. [11] Increased in cancer and nonmalignant patients
—* Breast and lung Susskind et al. [14] Increased in patients, decreased with RT
48,600.00 (PT) Prostate Morgia et al. [10] Increased with metastasis, decreased with treatment
108,000.00 (Met)
97,300.00 Castellano et al. [15] Increased with stage, decreased with treatment
56,500.00 Colorectal Tutton et al. [12] Decreased with treatment
OPG 1717.00 Neoblastoma Granchi et al. [16] Decreased over control
—* Prostate, Lung and Breast Mountzios et al. [17] Increased with metastasis
OPN 170,600.00 Prostate Castellano et al. [15] Increased with stage, decreased with treatment
RANKL 41.40 Neuroblastoma Granchi et al. [16] Increased with stage, metastasis, and unfavorable pathohistology
SDF-1α 2448.00 Breast Potter et al. [18]
2661.00 (RL) Hassan et al. [19] Increased metastasis below RL
Increased with metastasis
2717.00 (PT) Multiple Zannettino et al. [20]
3114.00 (Met) Myeloma
TGF-β1 4320.00 Breast Ivanovic et al. [21] Increased with stage and associated with metastasis
—* Decensi et al. [22] Inverse correlation with disease recurrence
3280.00 (RL) Nikolic-Vukosavljevic et al. [23] Levels above RL correlate with decreased survival
15,500.00 (Met) Prostate Shariat et al. [24] Increased with metastasis to LN and bone
5200.00 (PT)
15,250.00 (Met) Adler et al. [1] Increased with metastasis
2630.00 Breast and prostate Baselga et al. [25] Increased in patients, 1.4-fold higher than breast cancer patients
TIMP-1 240,000.00 Colorectal Holten-Andersen et al. [26] Increased in high stage
292,000.00 Breast Holten-Andersen et al. [26] Advanced breast cancer
108,700.00 Schrohl et al. [27]
133,000.00 Ovarian Manenti et al. [11] Increased over nonmalignant
—* Breast Susskind et al. [14] Increased in patients and remain high after RT
378,000.00 (PT) Lung Lower than controls, Increased with treatment
541,000.00 (Met)
TIMP-2 29,800.00 Ovarian Manenti et al. [11] Increased over nonmalignant
114,200.00 Thyroid Komorowski et al. [9] Increased over control
TNFα 2.24 (RL) Colorectal Kim et al. [3] Increased risk when over RL
3.95 (PT) Prostate Adler et al. [1] Increased with stage and metastasis
4.34 (Met)
TPO 232.00 CLL Koller et al. [28] Increased over controls, Increased with stage
—* Lung Werynska et al. [29] Increased in patients with reactive thrombocytosis
uPAR —* Ovarian Henic et al. [30] Increased with stage, indicates poor prognosis
1600.00 (PT) Prostate Shariat et al. [31] Increased in metastasis, decreased with treatment
2400.00 (Met)
VEGF 316.80 (RL) NSCLC Tamura et al. [13] Increased with stage. Levels above RL correlate with LN metastasis
—* Various Wynendaele et al. [32] Increased over controls
109.10 Ovarian Manenti et al. [11] Significantly higher than nonmalignant patients
31.30 (Met) Prostate Shariat et al. [33] Increased with stage and metastasis
9.91 (PT)
32.60 Breast Burstein et al. [34] Associated with decreased time to recurrence
74.30 Thyroid Komorowski et al. [9] No difference compared with control
AML indicates acute myeloid leukemia; CLL, chronic lymphocytic leukemia; LN, lymph node;Met, metastasis; NSCLC, non–small cell lung carcinoma; PT, primary tumor; RL, reference level; RT, radiotherapy.
*No exact values reported.
